Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Assessment of Quality of Life and Psychological Factors Among Women Diagnosed With Gestational Diabetes Mellitus

16. července 2026 aktualizováno: Harsh Kishore, Lovely Professional University

Summary of Research Protocol

Title: Quality of Life and Associated Psychological Factors in Women with Gestational Diabetes Mellitus

Background:

Gestational Diabetes Mellitus (GDM) is a common metabolic disorder of pregnancy characterized by glucose intolerance first recognized during pregnancy. The prevalence of GDM is increasing globally and in India due to the rising burden of obesity and diabetes. While much research has focused on the physiological and obstetric consequences of GDM, its impact on quality of life (QoL) and psychological well-being remains less explored. Women diagnosed with GDM often experience anxiety, stress, fear regarding pregnancy outcomes, and concerns about their own and their baby's health, which may negatively affect their quality of life and adherence to treatment.

Research Gap:

Existing studies have primarily concentrated on glycemic control and pregnancy outcomes, with limited attention to the psychosocial dimensions of GDM. The relationship between quality of life and psychological factors such as anxiety, depression, stress, and social support among women with GDM has not been adequately studied, particularly in the Indian population.

Aim:

To assess the quality of life among women with Gestational Diabetes Mellitus and examine its association with psychological factors.

Objectives:

To study the quality of life in women with GDM. To compare the quality of life between pregnant women with GDM and those without GDM.

To assess associated psychological factors, including anxiety, depression, stress, and perceived social support, among women with GDM.

Methodology:

A comparative cross-sectional study will be conducted among pregnant women aged 20-40 years attending the OPD and IPD services of Christian Medical College & Hospital, Ludhiana. Women diagnosed with GDM according to DIPSI criteria (2-hour post 75 g oral glucose load blood sugar ≥140 mg/dL) will constitute the study group, while pregnant women without GDM will serve as controls.

Data regarding demographic characteristics, obstetric history, medical history, family history of diabetes, and socioeconomic status will be collected using a structured case record form. Socioeconomic status will be assessed using the Modified Kuppuswamy Scale.

Psychological assessment will include:

GAD-7 for anxiety symptoms. PHQ-9 for depressive symptoms. MSPSS for perceived social support.

Quality of life will be assessed using a validated QoL questionnaire appropriate for women with GDM.

Sample Size:

Based on previous literature, a minimum sample size of 103 participants in each group (GDM and non-GDM) has been calculated, resulting in a total sample size of 206 participants.

Statistical Analysis:

Data will be analyzed using SPSS version 26.0. Quantitative variables will be compared using Student's t-test or Mann-Whitney U test, while categorical variables will be analyzed using Chi-square or Fisher's exact test. A p-value <0.05 will be considered statistically significant.

Expected Outcome:

The study is expected to provide insights into the quality of life of women with GDM and identify psychological and social factors associated with poorer QoL. The findings may help healthcare providers develop holistic and patient-centered management strategies that address not only glycemic control but also the psychosocial needs of pregnant women with GDM.

Přehled studie

Postavení

Nábor

Detailní popis

Diabetes is a major public health problem in India with prevalence rates reported to be between 4.6% and 14% in urban areas, and 1.7% and 13.2% in rural areas(1).

Gestational diabetes mellitus (GDM) is a transient metabolic disorder, characterized by hyperglycemia that occurs and is first diagnosed during pregnancy, and is expected to resolve after childbirth (2).

The onset of GDM puts a heavy strain on the positive connotation of pregnancy and is accompanied by feelings of fear, anxiety, uncertainty, a sense of losing control, elevated levels of stress, a poorer perception of one's health, reduced self-worth, and impaired QoL (3). Diabetes-specific instruments disregard the fact that women suffering from GDM expect their condition as temporarily limited to their pregnancy, unlike the chronic nature of diabetes mellitus type one or type two (4).

The usage of numerous different types of questionnaires for QoL assessment leads to inconsistent study findings on this topic, resulting in heterogeneous recommendations. Accordingly, it seems reasonable to establish a solid foundation for further research by developing and validating an appropriate patient-reported outcome measure for QoL assessments in GDM. Mokhlesi et al (5) have completed important work by introducing the Persian questionnaire GDMQ-36 for the assessment of disease-specific QoL in women with GDM, which has been proven to be reliable and valid for the Iranian population.

To our knowledge, it is so far the only questionnaire worldwide tailored to the QoL of gestational diabetics that incorporates all the mentioned aspects due to the fact that it is exactly tailored to the needs as well as disease- and treatment-related challenges gestational diabetics are facing. It contains 36 questions and consists of five aspects: (1) concerns about high-risk pregnancy, (2) perceived constraints, (3) complications of GDM, (4) medication and treatment, and (5) support In managing Gestational Diabetes Mellitus (GDM) is the lack of studies that explore how a

woman's personal living conditions and biopsychosocial factors affect her adherence to treatment and overall quality of life (QoL). Aspects such as fear of hypoglycemia or concerns about fetal health can influence a woman's acceptance of treatment, even if the treatment is medically effective. Research is needed to understand how these personal and psychosocial factors impact a woman's ability to follow treatment plans and how improving QoL can enhance treatment adherence. By focusing on personalized care that takes these factors into account, Present study help create more effective and supportive treatment strategies for women with GDM.

Typ studie

Pozorovací

Zápis (Odhadovaný)

206

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Harsh Kishore Mr, M Pharmacy (Pharmacology)
  • Telefonní číslo: +91 724 864 8989
  • E-mail: harsh.42300149@lpu.in

Studijní záloha kontaktů

  • Jméno: Harsh Kishore, M. Pharmacy (Pharmacology)
  • Telefonní číslo: +91 7696660211

Studijní místa

    • Punjab
      • Ludhiana, Punjab, Indie, 141008
        • Nábor
        • Christain Medical College and Hospital
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý

Přijímá zdravé dobrovolníky

Ano

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

The study will be conducted on all Pregnant females in age group of 20-40 years

Popis

Inclusion Criteria:

  • 1) All Pregnant females admitted to Christian Medical College & Hospital, Ludhiana. (OPD+IPD).

    2) Age group between 20-40 years.

    3) Females who have given consent for the study.

Exclusion Criteria:

  • 1) Subjects not willing to participate.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

Kohorty a intervence

Skupina / kohorta
Pregnancy with Gestational diabetes mellitus (GDM)
Pregnancy with without GDM

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Quality of Life as measured by the Gestational Diabetes Mellitus Quality of Life Questionnaire (GDMQ-36)
Časové okno: Baseline
Quality of life in women with Gestational Diabetes Mellitus (GDM) will be assessed using the disease-specific GDMQ-36 questionnaire. The questionnaire consists of 36 items across 5 domains: (1) concerns about high-risk pregnancy, (2) perceived constraints, (3) complications of GDM, (4) medication and treatment, and (5) support. Total score ranges from 0 to 100, with higher scores indicating better quality of life. This will be assessed in women with GDM at baseline.
Baseline

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Prevalence of Depressive Symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9)
Časové okno: Baseline
Depressive symptoms in women with GDM will be assessed using the PHQ-9 questionnaire. Each of the 9 items is scored on a Likert scale from 0 to 3 (0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day). Total score ranges from 0 to 27. A score of 10 or higher indicates the presence of depressive symptoms.
Baseline
Level of Perceived Social Support as measured by the Multidimensional Scale of Perceived Social Support (MSPSS)
Časové okno: Baseline
Perceived social support in women with GDM will be assessed using the MSPSS, a 12-item validated tool evaluating support from three sources: family, friends, and significant other. Each item is rated on a 7-point Likert scale (1 = very strongly disagree to 7 = very strongly agree). Average score ranges from 1 to 7. Social support is categorized as low (< 2), moderate (3-5), or high (> 5).
Baseline
To assess the association of serum Vitamin D with Gestational Diabetes Mellitus.
Časové okno: Baseline
To assess the association of serum Vitamin D levels with the diagnosis of Gestational Diabetes Mellitus. Serum Vitamin D (ng/mL) levels will be measured in all participants at baseline. Vitamin D levels will be categorized as deficient (< 20 ng/mL), insufficient (20-29 ng/mL), or sufficient (≥ 30 ng/mL).
Baseline
To assess the association of serum Cortisol levels with Gestational Diabetes Mellitus.
Časové okno: Baseline
Serum Cortisol levels will be measured in all participants at baseline. Cortisol levels will be categorized using a cut-off of 17.66 µg/L.
Baseline

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Tapasya Dhar, Christain Medical College and Hospital
  • Vrchní vyšetřovatel: Rakesh Kumar, PhD Pharmacology, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara -144411, Punjab, India,

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

14. května 2026

Primární dokončení (Odhadovaný)

31. prosince 2026

Dokončení studie (Odhadovaný)

31. prosince 2026

Termíny zápisu do studia

První předloženo

23. června 2026

První předloženo, které splnilo kritéria kontroly kvality

16. července 2026

První zveřejněno (Aktuální)

21. července 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

21. července 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

16. července 2026

Naposledy ověřeno

1. července 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit